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BMP9 Mutations Cause a Vascular-Anomaly
Syndrome with Phenotypic Overlap
with Hereditary Hemorrhagic Telangiectasia
Whitney L. Wooderchak-Donahue,1 Jamie McDonald,2 Brendan O’Fallon,1 Paul D. Upton,3 Wei Li,3
Beth L. Roman,4 Sarah Young,4 Parker Plant,1 Gyula T. Fu¨lo¨p,5,6 Carmen Langa,5,6
Nicholas W. Morrell,3 Luisa M. Botella,5,6 Carmelo Bernabeu,5,6 David A. Stevenson,7 James R. Runo,8
and Pinar Bayrak-Toydemir1,2,*
Hereditary hemorrhagic telangiectasia (HHT), the most common inherited vascular disorder, is caused by mutations in genes involved
in the transforming growth factor beta (TGF-b) signaling pathway (ENG, ACVRL1, and SMAD4). Yet, approximately 15% of individuals
with clinical features of HHT do not have mutations in these genes, suggesting that there are undiscovered mutations in other genes for
HHT and possibly vascular disorders with overlapping phenotypes. The genetic etiology for 191 unrelated individuals clinically sus-
pected to have HHT was investigated with the use of exome and Sanger sequencing; these individuals had no mutations in ENG,
ACVRL1, and SMAD4. Mutations in BMP9 (also known as GDF2) were identified in three unrelated probands. These three individuals
had epistaxis and dermal lesions that were described as telangiectases but whose location and appearance resembled lesions described
in some individuals with RASA1-related disorders (capillary malformation-arteriovenous malformation syndrome). Analyses of the
variant proteins suggested that mutations negatively affect protein processing and/or function, and a bmp9-deficient zebrafish model
demonstrated that BMP9 is involved in angiogenesis. These data confirm a genetic cause of a vascular-anomaly syndrome that has
phenotypic overlap with HHT.Hereditary hemorrhagic telangiectasia (HHT [MIM
187300 and 600376]) is an autosomal-dominantly
inherited vascular-malformation syndrome characterized
by telangiectases and arteriovenous malformations
(AVMs) and has an incidence of 1 in 10,000 individ-
uals.1 Hallmark features are recurrent epistaxis due to
telangiectases of the nasal mucosa; telangiectases on the
lips, hands and oral mucosa; solid-organ AVMs, parti-
cularly of the lungs, liver, and brain; and a family history
of the same. Presentation with three of these criteria
is considered diagnostic for HHT.2 The dermal telangiecta-
ses are typically pinpoint to pinhead sized, very specif-
ically concentrated on the hands, face and lips, and not
diffuse. Telangiectases on the limbs and trunk are not
characteristic.
Currently, all known genetic defects that cause HHT are
found within the transforming growth factor beta (TGF-b)
signaling pathway. Mutations in endoglin (ENG [MIM
131195]), activin A receptor type II-like 1 (ACVRL1, also
known as ALK1 [MIM 601284]), and SMAD4 (MIM
600993) cause HHT type 1, HHT type 2, and the combined
juvenile polyposis (JP) and HHT (JP-HHT) syndrome,
respectively.3–5 Approximately 15% of individuals identi-
fied clinically as having HHT currently have no known ge-
netic cause,6 suggesting that there are undiscovered genes
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tures of capillary-malformation (CM)-AVM syndrome
(CM-AVM [MIM 608354]), caused by mutations in RASA1
(MIM 139150).7–10 Recurrent nosebleeds have not been
described, and the typical dermal telangiectases generally
differ fromHHT in location and appearance. The telangiec-
tases seen in CM-AVM include both the small punctate
lesions that characterize HHT and the larger telangiectases
referred to as CMs. The punctate telangiectases in CM-
AVM are more commonly diffuse and tend to cluster in a
region of the trunk or limbs (M. Vikkula, personal commu-
nication).
We first performed exome sequencing in 38 unrelated
individuals reported to have HHT2 (by physicians who
had ordered HHT genetic testing) but in whom no muta-
tion had been identified in ENG, ACVRL1 or SMAD4.
Informed consent was obtained from all individuals
(approved by the institutional review board [00028740]
at the University of Utah). Samples were enriched with
the use of exome-targeted biotinylated RNA baits (SureSe-
lect 50 Mb) and sequenced with 23 100 bp paired-end
reads (HiSeq2000, Illumina). The Burrows-Wheeler Aligner
(0.5.9)11 and the Genome Analysis Toolkit (v.1.6)12 were
used for data analysis. To reduce the number of false-posi-
tive variant calls, we used raw variant sets as input to a
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Table 1. BMP9 Variants and Case Phenotypes
Individual Clinical Description
Nucleotide
Change
Protein
Change
Presence in
Populationa
Family
Segregation Variant Classification
1 epistaxis, telangiectasia, first-degree relative
reported to have HHT
c.254C>T p.Pro85Leu absent NA pathogenic
2 epistaxis, telangiectasia or CM (back,
shoulders, mouth, face), AVM (thumb),
parent and sibling with history of epistaxis
c.203G>T p.Arg68Leu absent yesb pathogenic
3 epistaxis, telangiectasia (80–100 on the left
arm and shoulder, 2 on the right palm, 1
possible on the lip); a parent reports frequent
epistaxis as a child and teen
c.997C>Tc p.Arg333Trpc 0.004 NA suspected to be pathogenic
4 CM and hemihypertrophy c.51C>Ac 50 UTRc absent NA suspected to be benign
All nucleotide changes were heterozygous. BMP9 RefSeq accession number NM_016204 was used. ‘‘NA’’ stands for not available.
aPresence in population refers to the presence of the variant in 1000 Genomes, dbSNP, or 5,400 control exomes.
bFather and sister with epistaxis also carry the mutation.
cIdentified by Sanger sequencing.discarded resulting variants with VQRLOD scores less than
10.0.
We prioritized variants by subjecting them to a two-part
classification procedure. First, we computed SIFT,13 Poly-
Phen-2,14 MutationTaster,15 GERPþþ,16 PhyloP,17 LRT,18
and SiPhy19 scores for all nonsynonymous variants. We
computed scores by consulting a precomputed database
of all possible scores distributed with the dbNSFP package,
version 2.0.20We combined these scores into a single value
by using a linear weighting scheme, and this value re-
flected the overall damage to the gene in question. Next,
we employed phenotypic ranking by using the VarRanker
algorithm (B.O., unpublished data).
Pathogenic missense variants were identified in BMP9
(MIM 605120) in 2 of the 38 samples: c.254C>T (p.Pro85-
Leu) and c.203G>T (p.Arg68Leu) (Figures S1A and S1B,
available online, and Table 1) (RefSeq accession number
NM_016204.1). Neither BMP9 variant was present in
publically available databases, the affected residues were
highly conserved (from humans to zebrafish), and their
corresponding mutations were predicted to be damaging
by computing algorithms (Table S1).13–15
Next, BMP9 exons were Sanger sequenced in an addi-
tional 153 unrelated individuals who had been referred
for molecular genetic testing as a result of suspicion of
HHT by a referring physician, although most (86%) met
two of the established diagnostic criteria for HHT and the
other 14% met three diagnostic criteria. Another variant
(c.997C>T [p.Arg333Trp]) was identified in one individual
within this group (Figure S1C and Table 1). Although
this variant has been previously reported in dbSNP
(rs35129734), it is potentially disease causing because it
is very rare (variant frequency of 0.004), the affected resi-
due is strictly conserved among higher vertebrates, and
the variant is predicted to be deleterious by SIFT,13 Poly-
Phen-2,14 and MutationTaster.15
All three individuals identified with a BMP9 mutation
had dermal lesions described as telangiectases, yet a
detailed review of the location and appearance of their le-The Americansions suggested a cutaneous phenotype that differs from
classic HHTand has some resemblance to lesions described
in individuals with RASA1-related disorders (CM-AVM).
Therefore, BMP9 exons were also Sanger sequenced for 60
unrelated individuals who had been clinically suspected
of having a mutation in RASA1 by their referring physician
but in whom no mutation was identified in this gene. One
variant not present in publically available databases was
identified in the BMP9 50 UTR region (c.51C>A) in one
individual (Table 1), who had macrocephaly, extensive
CMs, and hemihypertrophy. Given that the individual’s
unaffected mother had the same 50 UTR variant, it is not
likely that this variant causes the individual’s phenotype.
Individual 1 (c.254C>T [p.Pro85Leu]) is a 33-year-old
female whose onset of epistaxis occurred in early child-
hood. She reports that her nosebleeds were themost signif-
icant during childhood—they occurred two to six times a
week—but were still significant enough in her twenties
to warrant treatment by nasal cautery. She reported that
she currently has approximately three nosebleeds a week
but that they are minor in duration relative to how they
were during childhood. She had several cutaneous telangi-
ectases on her chest and face. No solid-organ AVMs were
known, but she had not been screened for solid-organ
AVMs. Her father died suddenly at the age of 45 years,
and according to the family, HHTwas suspected on the ba-
sis of autopsy findings. Unfortunately, this report was not
available to confirm details, but it was the suggestion of
HHT in her father years ago that led this individual to
seek consultation regarding her epistaxis and cutaneous
lesions. A sibling had recurrent spontaneous nosebleeds
(approximately two per week) and a stroke of unknown eti-
ology at the age of 43 years. No family members were avail-
able for examination or variant analysis.
Individual 2 (c.203G>T [p.Arg68Leu]) is a 37-year-old
female whose onset of epistaxis occurred at approximately
30 years of age. The frequency of her nosebleeds varied
from daily to once every 1–2 weeks. The individual had
15–20 dermal vascular malformations on her face, mouth,Journal of Human Genetics 93, 530–537, September 5, 2013 531
Figure 1. Cutaneous Vascular Lesions in Individual 2
Shown are themiddle digit of the left hand (A), the dorsal aspect of
the right hand (B), several of approximately 20 lesions on the back
and shoulders (C), and a vascular lesion previously treated by laser
ablation on the right jawline (D).upper chest, upper mid back, and hands, and they were
first noticed when she was about 30 years old (Figure 1).
The individual reported that the larger malformations
had faded from a darker to lighter pink over time. An
MRI of the brain did not show AVMs. Her father and sister
reported infrequent but recurring nosebleeds, but they
were not available for clinical examination. DNA was ob-
tained from saliva, and the BMP9 c.203G>T (p.Arg68Leu)
variant was identified in both the father and the sister.
Individual 2 had abnormal liver enzymes and portal hy-
pertension. A liver MRI showed findings suggestive of the
hepatic vascularfindings seen inHHT. Inparticular, thearte-
rial phase was slightly heterogeneous, and several smaller
branches of the hepatic artery were prominent and slightly
corkscrew in configuration. Several small focal enhancing
nodules were noted on the arterial phase that equilibrated
in other phases and were not visible on other sequences,
suggesting small focal nodular hyperplasia. However, this
individual had also been diagnosedwith hepatopulmonary
syndrome, and the cause of her hepatic issues is not clear.532 The American Journal of Human Genetics 93, 530–537, SeptembIndividual 3 (c.997C>T [p.Arg333Trp]) is a 14-year-old
male whose onset of epistaxis occurred at approximately
3 years of age. Frequency of epistaxis had ranged from
approximately once per week to several times per day. He
had 80–100 telangiectases on his left upper extremity
from wrist to shoulder, two telangiectases on the palm of
his right hand, and one possible telangiectasia on his lower
lip. The pathology report of a biopsy of the lesions
confirmed them to be telangiectases. No solid-organ
involvement (AVM) was known, but he was not screened
by the referring physician. Per family history report, his
father had nosebleeds of more than once per week in
elementary school until his early teens, but none in recent
years. DNA was not available from the father for variant
analysis.
To characterize the functional effects of the three BMP9
variants identified, we evaluated BMP9 levels and process-
ing into the mature, active form of the protein21
(Figure 2A). Comparison of plasmid-transfected human
embryonic kidney (HEK) EBNA cell lysates and superna-
tants by immunoblot using an antibody specific to mature
BMP9 revealed that the processing of the p.Arg68Leu and
p.Arg333Trp variants to mature BMP9 was far less efficient
than that of the wild-type (WT) BMP9, whereas processing
of the p.Pro85Leu variant was less impaired (Figure 2B).
This reduction of mature BMP9 in the supernatants was
later confirmed with a specific ELISA in HEK cells
(Figure 2C), as well as in the hepatoma cell line HepG2
(Figure S2). Importantly, control culture supernatants
from HepG2 cells showed only low background levels of
BMP9 (<10 pg/ml) (data not shown). Thus, all three vari-
ants altered BMP9 processing in vitro. Unfortunately,
serum samples were not available for testing BMP9 levels
in these individuals.
To assess the relative activities of the WT and variant
forms of BMP9, we examined their ability to induce BRE-
luciferase activity in C2C12 cells transfected with human
ALK1 (Figures 2D–2F). Assays of these BMP9 variants in
C2C12 cells transfected with ALK1 revealed that the
p.Arg68Leu and p.Pro85Leu variants exhibited less activity
than did the WT BMP9 at 10 pg/ml (p.Arg68Leu: 79.2%5
10.3% of WT; p.Pro85Leu: 82.2% 5 7.6% of WT) and 30
pg/ml (p.Arg68Leu: 78.9% 5 4.3% of WT; p.Pro85Leu:
78.6% 5 7.2% of WT) equivalent dilutions, but the
p.Arg333Trp variant did not (10 pg/ml equivalent:
100.92% 5 11.8% of WT; 30 pg/ml equivalent: 99.6% 5
2.1% ofWT) (Figure 2F). No luciferase activity was detected
in the conditioned medium from HEK EBNA cells trans-
fected with the empty pCEP4 vector (data not shown).
We also tested the biological activity of the BMP9 vari-
ants by measuring production of alkaline phosphatase in
the ATDC5 mouse chondrogenic cell line. Alkaline phos-
phatase is a widely accepted marker of the signaling
pathway induced by different BMPs and by BMP9 in partic-
ular.22 At the same protein concentration (1 ng/ml), the
p.Arg68Leu, p.Pro85Leu, and p.Arg333Trp BMP9 variants
showed less activity than did the WT protein (Figure 3).er 5, 2013
Figure 2. BMP9 Variants Alter Protein Processing and Binding of Ligands to ALK1
(A) BMP9 diagram depicting the alteration locations, prodomain, and mature protein. The BMP9 precursor encodes a signal sequence
from amino acids 1–22, a prodomain from amino acids 23–319 (proBMP9), and the mature BMP9 from amino acids 320–429. Secreted
BMP9 comprises amino acids 23–429; furin-type proteases cleave its prodomain to generate mature BMP9.21
(B) Plasmids encoding humanWT BMP9 or the p.Arg68Leu, p.Pro85Leu, or p.Arg333Trp variants were transfected into HEK EBNA cells.
Cell lysates and conditioned media were fractionated with nonreducing SDS-PAGE and immunoblotted for BMP9 with a mouse
monoclonal BMP9 antibody (clone #360107, R&D Systems). For cell lysates, equal protein loading was confirmed by subsequent immu-
noblotting for a-tubulin and densitometry of the bands normalized to the a-tubulin bands. Supernatants were also fractionated and
immunoblotted for BMP9. A parallel gel was run and stained with Coomassie blue. For verification, the Coomassie-stained bands
were sequenced. WT and variant BMP9 proteins fractionated as three bands corresponding to the mature BMP9 dimer associated
with both prodomains (~125–150 kDa), the mature BMP9 dimer associated with a single prodomain (75 kDa), and mature BMP9
(22 kDa). Mature BMP9 is indicated by an arrow. Densitometry graphs are also shown.
(C) BMP9 levels were determined by a specific ELISA (n¼ 3). The ELISAwas developed with a colorimetric substrate comprising 1 mg/ml
4-nitrophenyl phosphate disodium salt hexahydrate in 1 M diethanolamine (pH 9.8) containing 0.5 mM MgCl2. The assay was devel-
oped in the dark at room temperature, and the absorbance was measured at 405 nm. Unknown values were extrapolated from the stan-
dard curve with a 4-parameter log curve fit.
(D) C2C12 cells were transfected with human ALK1 and treated with R&D Systems BMP9 (between 0.1 and 3,000 pg/ml) or WT BMP9
diluted to equivalent activities. Cells exposed to Lipofectamine (‘‘Lipo’’) alone were treated in parallel with R&D Systems BMP9. All cells
were cotransfected with BRE-luciferase and pTK-Renilla. BMP9-driven firefly luciferase responses were normalized to Renilla activity. Data
(legend continued on next page)
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Taken together, these experiments demonstrate that the
three BMP9 variants affect the biological activity of BMP9.
Next, we performed bmp9 knockdown experiments
in zebrafish to identify whether they would exhibit a
vascular phenotype similar to HHT. Tg(kdrl:egfp)la116;Tg
(gata1.DsRed2)sd2 zebrafish embryos23,24 were injected at
the 1- to 4-cell stage with 7 ng bmp9 translation-blocking
morpholino (50-GGAGCAAATGTCCTACGCGCCACAT-30)
or standard control morpholino (GeneTools). Compared
to control morphants, bmp9 morphants exhibited small
but significant decreases in both anterior-posterior and
dorsal-ventral axes, but trunk and tail anatomy were other-
wise normal (Figures 4A and 4B). Vascular patterning in
bmp9 morphants was relatively normal, although subtle
defects were detected in maturation of the caudal vein.
Although all control morphants exhibited a dominant
ventral-vein return by 2 days postfertilization (dpf) (n ¼
86/86), in bmp9 morphants the caudal venous plexus
failed to resolve and both dorsal and ventral veins
continued to carry blood flow (n ¼ 76/91, 83.5%; Figures
4C and 4D). This phenotype persisted as late as 5 dpf, sug-
gesting that it was not the result of developmental delay
but instead reflected impaired remodeling. Repeating the
knockdown of bmp9with a splice-blocking morpholino re-
sulted in the same venous remodeling defect (data not
shown), supporting a role for BMP9 in angiogenesis. In ze-
brafish, alk1 mutations result in robust cranial AVMs.25,26
However, we detected no cranial AVMs in bmp9morphants
(n ¼ 0/207), suggesting that other ligands such as BMP10
might compensate for BMP9 in the development of these
cranial vessels (B.R., unpublished results).
Overall, three missense variants in BMP9 were identified
in 191 individuals with features of HHT. These three amino
acids are conserved from humans through zebrafish, pre-
dicted to be damaging, and shown by in vitro studies to
alter BMP9 processing to the mature form and BMP9 activ-
ity to varying degrees (Figures 2 and 3). Furthermore,
knockdown of bmp9 in zebrafish resulted in defects in
venous remodeling (Figure 4), supporting a role for BMP9
in angiogenesis. This is consistent with the reported role
for BMP signaling during vascular development: blocking
BMP9 with a neutralizing antibody in newborn mice
significantly increased retinal vascular density.27 Surpris-are the mean5 SEM (n ¼ 4 wells) for a representative experiment. T
mercial BMP9 for the establishment of an activity profile. C2C12 ce
(mature BMP9, amino acids 320–429) at concentrations as low as 1
(E) Supernatants from (B) were diluted so that there were equal amoun
BMP9. The activity profiles for WT BMP9 were similar to the comme
centrations of 1 and 10 pg/ml. For each variant, relative supernatant v
WT BMP9 were determined.
(F) C2C12 cells were transfected with human ALK1 and treated with
treated in parallel with WT BMP9. All cells were cotransfected with
sponses were normalized to Renilla activity. The range over which A
n ¼ 4 wells from a representative experiment. Top dilutions were
(p.Arg333Trp), and serial dilutions of each BMP9 variant were prepar
of these BMP9 variants in C2C12 cells transfected with ALK1 reve
activity thanWT BMP9 at 10 pg/ml (p.Arg68Leu: 79.2%5 10.3% of W
78.9%5 4.3% of WT; p.Pro85Leu: 78.6%5 7.2% of WT) equivalen
lent: 100.92%5 11.8% of WT; 30 pg/ml equivalent: 99.6%5 2.1%
534 The American Journal of Human Genetics 93, 530–537, Septembingly, Bmp9-knockout mice did not show any vascular
phenotype in retinal vascularization, and no abnormal
retinal vascularization was noted in the three individuals
with BMP9 variants. Furthermore, BMP9 specifically plays
a physiologic role in the control of adult blood-vessel
maintenance and angiogenesis by targeting ALK1 on endo-
thelial cells.28
BMP9 exerts its functional effects by binding to specific
endothelial cell surface receptors, namely the auxiliary re-
ceptor endoglin and the serine-threonine kinase ALK1,
both members of the highly conserved TGF-b superfamily.
Then, the BMP9-dependent activation of ALK1 leads to the
phosphorylation of Smad1, Smad5, and Smad8, and the re-
sulting phospho-Smad proteins associate with Smad4 to
form a Smad complex that translocates to the nucleus to
regulate gene expression in human microvascular endo-
thelial cells. In addition, ALK1 activation by BMP9 further
increases by overexpression of the coreceptor endoglin.28
Furthermore, BMP9 signaling via endoglin promotes a
switch from a chemokine-responsive autocrine phenotype
to a chemokine-nonresponsive paracrine state that re-
presses endothelial cell migration and promotes vessel
maturation.29 These data strongly suggest the involvement
of BMP9 in a common TGF-b signaling pathway shared by
ALK1, endoglin, and Smad4. Because mutations in ENG,
ALK1, and SMAD4 give rise to different types of HHT
(HHT1, HHT2, and JP-HHT, respectively), it can be postu-
lated that alterations in BMP9, the upstream component
of this signaling route, cause a vascular-malformation syn-
drome with phenotypic overlap with HHT (Figure 5). Sup-
porting this view, many of the mutations described in ENG
involve its orphan domain, a region responsible for bind-
ing to BMP9.30–33
We observed that the p.Arg68Leu and p.Arg333Trp vari-
ants dramatically affected the degree of processing in the
HEK EBNA expression system and thus reduced the
amount of mature BMP9 that was being produced inside
the expressing cells. Furthermore, the secretion of the
mature and proBMP9 forms of the p.Arg68Leu and
p.Arg333Trp variants was dramatically reduced. Intrigu-
ingly, the p.Pro85Leu variant also exhibited reduced levels
of the proBMP9 form, but the processing was less impaired
than in the other two variants. In addition to displayinghe activity of the WT protein was titrated in comparison to com-
lls transfected with ALK1 became sensitive to commercial BMP9
pg/ml.
ts of mature BMP9 in themedia conditioned withWTand variant
rcial BMP9 profile, albeit with reduced activity at the lowest con-
olumes necessary for achieving equivalent amounts of the mature
WT or variant BMP9. Cells exposed to Lipofectamine alone were
BRE-luciferase and pTK-Renilla. BMP9-driven firefly luciferase re-
LK1 activation occurs is indicated. Data are the mean 5 SEM for
prepared at 1 (WT) to 8.3 (p.Arg68Leu) to 1.3 (p.Pro85Leu) to 4
ed with the same dilution series as with commercial BMP9. Assays
aled that the p.Arg68Leu and p.Pro85Leu variants exhibited less
T; p.Pro85Leu: 82.2%5 7.6% of WT) and 30 pg/ml (p.Arg68Leu:
t dilutions, but the p.Arg333Trp variant did not (10 pg/ml equiva-
of WT).
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Figure 3. Missense Substitutions in BMP9 Alter Protein Activity
The mouse chondrogenic cell line ATDC5 was incubated with
1 ng/ml of WT BMP9 or the p.Arg68Leu, p.Pro85Leu, or
p.Arg333Trp variants produced in HepG2 cells, as shown in
Figure S2. Alkaline phosphatase activity was measured in permea-
bilized ATDC5 cells with the use of p-nitrophenyl phosphate as a
soluble substrate. Relative activity units are shown in the vertical
axis. *p < 0.001; **p < 0.07.changes in processing, the p.Arg68Leu and p.Pro85Leu
BMP9 variants exhibited slightly reduced activity with
ALK1. A reduction in activity is consistent with these mu-
tations’ being in a region that might interact with ALK1.21
We did not observe reduced activity of the p.Arg333Trp
variant in our C2C12 activity assay, and we observed
only a slight reduction in activity of the same variant in
ATDC5 cells (Figure 3). This mutationmight affect a region
that binds to type II or type III receptors, including endo-
glin. In summary, it is likely that the different BMP9 vari-
ants each affect particular aspects of BMP9 processing,
secretion, and receptor activity and thus lead to reduced
functionality of BMP9.
In our cohort of 191 individuals suspected to have HHT
on examination by a referring physician, 3 (1.6%, or 0.24%with an APO L 203/1.00 water-immersion objective, standard visib
Corp.). EGFP was imaged at 900 nm, and DsRed2 was imaged at 561 n
projections were generated with MetaMorph 7.7 (Molecular Devices
The Americanof the total number of individuals with suspected HHT) of
them were found to have a BMP9 variant. These three indi-
viduals all had epistaxis and dermal lesions described as tel-
angiectases; however, the lesions were less concentrated on
the hands and mouth than in individuals with mutations
in ENG, ACVRL1, or SMAD4. In individual 2, the size and
appearance of some lesions were more similar to the ‘‘atyp-
ical CM’’ seen in CM-AVM. In individual 3, the lesions were
more punctate and resembled those in HHT in appearance,
but the number and distribution were more typical of
telangiectasia described in CM-AVM. The variants were
shown to be present in two symptomatic first-degree
relatives of one index case. However, no family members
were available for examination by our group.
Molecular screening of BMP9 in individuals suspected to
have HHT should be considered in individuals with
epistaxis and small blanching vascular lesions on the
upper body and trunk rather than limited to the hands,
face, and mouth (as is typical of HHT). It is of note that
the individuals in this study, and many with HHT, have
relatively infrequent, mild nosebleeds not routinely
reported to physicians during medical history. Because of
the small number of individuals presented here and the
fact that evaluation for solid-organ AVMs was not
routinely performed, little can be concluded about the
presence or absence of internal AVMs in this disorder.
However, in the one individual in which imaging of solid
organs (brain, lungs, and liver) was performed, liver find-
ings similar to those seen in HHTwere noted. Interestingly,
BMP9 has been reported to be predominantly expressed by
the hepatocytes,34 suggesting that the liver vasculature is a
potential target of BMP9 deficiency.
Continuedmolecular analysis and clinical description in
families affected by various patterns of CM and/or telangi-
ectases will lead to continued expansion and refinement of
hereditary conditions characterized by cutaneous vascular
lesions. Both will help guide proper surveillance and
possible interventions for this group of individuals.Figure 4. bmp9 Morphant Zebrafish
Display Impaired Venous Remodeling
(A and B) Bright-field images of live em-
bryos; boxed areas in (A) and (B) designate
regions of focus in (C) and (D), respec-
tively. The scale bar represents 200 mm.
(C and D) Two-photon confocal images of
circulation in the caudal vein plexus at 2
dpf. Endothelial cells are green, and red
blood cells are magenta. The scale bar rep-
resents 50 mm. Abbreviations are as fol-
lows: DV, dorsal vein; and VV, ventral vein.
Zebrafish Tg(kdrl:egfp);Tg(gata1:dsRed2)
embryos were injected at the 1- to 4-cell
stage with 7 ng control morpholino (A
and C) or 7 ng bmp9 morpholino (B and
D) and imaged at 2 dpf. Embryos were
imaged with a Leica TCS SP5 confocal
microscope (Leica Microsystems) outfitted
le lasers, and Mai Tai DeepSee IR laser (Spectra-Physics, Newport
m. Z-series were collected at 2 mm intervals, and two-dimensional
). All images show left anterior lateral views.
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Figure 5. BMP9 and the TGF-b Signaling Pathway
BMP9 binds to specific type I and type II cell-surface receptors (R-I
and R-II, respectively) that exhibit serine-threonine kinase activ-
ity, as well as to the auxiliary receptor endoglin. Upon ligand bind-
ing, R-II transphosphorylates ALK1 (R-I), which then propagates
the signal by phosphorylating receptor-regulated (R-Smads)
Smad1, Smad5, and Smad8 (‘‘Smad1/5/8’’). Once phosphorylated,
R-Smads form heteromeric complexes with a cooperating homo-
log, Smad4, and translocate into the nucleus where they regulate
the transcriptional activity of target genes, including Id1. Endo-
glin, ALK1, and Smad4 are encoded by ENG, ACVRL1 and
SMAD4, respectively, whose pathogenic mutations give rise to
HHT1, HHT2, and JP-HHT, respectively. BMP9 is encoded by
GFDF2, whose pathogenic variants are described here. The
following abbreviation is used: GTM, general transcription ma-
chinery. This figure was adapted from Figure 2 in Ferna´ndez
et al.30Supplemental Data
Supplemental Data include two figures and one table and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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